Advertisement
Collaboration › Details
Mainz Biomed–Cantor Fitzgerald: investor conference, 202309 supply service Mainz Biomed presents at CF Global Healthcare Conference 2023 in NY
Period | 2023-09-28 | |
Region | New York, NY | |
Country | United States (USA) | |
Partner, 1st | Mainz Biomed N.V. (Nasdaq: MYNZ) | |
Partner, 2nd | Cantor Fitzgerald & Co. | |
Group | Cantor Fitzgerald (Group) | |
Product | Cantor Global Healthcare Conference 2023 New York | |
Product 2 | ColoAlert® colorectal cancer screening test | |
Person | Baechler, Guido (Mainz Biomed 202111 CEO before Singulex 201305– CEO before SVP Operations before Roche Dx) | |
Mainz Biomed N.V.. (6/15/23). "Press Release: Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference". Mechelen.
Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that Guido Baechler, Chief Executive Officer, will present at the Cantor Fitzgerald Global Healthcare Conference which takes place September 26-28, 2023 in New York City.
This year’s conference is expected to bring together key opinion leaders from public and private companies for in-depth discussions on the developments and trends shaping diagnostics and other healthcare-related industry sectors.
Mr. Baechler’s presentation will take place on September 28th at 10.20am ET and will be available to watch via video webcast both live, and on replay for 90 days post event, by following this access link. He will be available for 1-on-1 meetings with investors after the presentation and throughout the day (28th).
For more information on the Global Healthcare Conference, please visit https://www.cantor.com/our-company/conferences/global-healthcare-conference-2023/.
About Mainz Biomed NV
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. ColoAlert® is currently marketed across Europe. The Company is running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test. To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter/X and Facebook.
For media inquiries –
In Europe:
MC Services AG
Anne Hennecke/Caroline Bergmann
+49 211 529252 20
[email protected]
In the U.S.:
Josh Stanbury
+1 416 628 7441
[email protected]
For investor inquiries, please contact [email protected]
Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on April 7, 2023. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.
Record changed: 2023-09-25 |
Advertisement
More documents for Mainz Biomed N.V. (Nasdaq: MYNZ)
- [1] Mainz Biomed N.V.. (11/29/24). "Press Release: Mainz Biomed Announces Stock Split". Berkeley, CA & Mainz....
- [2] Mainz Biomed N.V.. (11/12/24). "Press Release: Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets". Berkeley, CA & Mainz....
- [3] Mainz Biomed N.V.. (9/4/24). "Press Release: Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert". Berkeley, CA & Mainz....
- [4] Mainz Biomed N.V.. (11/15/23). "Press Release: Mainz Biomed Announces Closing of $5.0 Million Registered Direct Offering". Berkeley, CA & Mainz....
- [5] Mainz Biomed N.V.. (11/9/23). "Press Release: Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test". Berkeley, CA & Mainz....
- [6] Mainz Biomed N.V.. (10/26/23). "Press Release: Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations". Berkeley, CA & Mainz....
- [7] Mainz Biomed N.V.. (6/29/23). "Press Release: Mainz Biomed Secures up to $50M in New Funding". Berkeley, CA....
- [8] Mainz Biomed N.V.. (6/15/23). "Press Release: Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference". Mechelen....
- [9] Mainz Biomed N.V.. (4/26/22). "Press Release: Mainz Biomed Appoints Darin Leigh as Chief Commercial Officer". Berkeley, CA & Mainz....
- [10] Mainz Biomed N.V.. (1/28/22). "Press Release: Mainz Biomed Announces the Closing of its $25.8 Million Public Follow-on Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares". Berkeley, CA & Mainz....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top